Effect of Plant Extract [FGF271] on Estrogen Replacement

식물유래 추출물(FGF271)의 여성호르몬 대체 효과

  • Published : 2002.08.01

Abstract

A certain group of phytochemicals such as isoflavone have been proven to act as a phytoestrogen. After thorough the study of different bibliographic herbs excluding soybeans, dates, pomegranates, and other publicized plants, three different edible herbs by Korean Food Regulation were extracted for the animal study on the effect of estrogen replacement. The herbal extract(FGF271) has been orally administered into 51 weeks old partial ovariectomized rats for 5 weeks with the different dosages of 100 and 1,000 mg/kg, respectively. It was observed that 1) serum estrogen level was increased in both 100 and 1,000 mg/kg group, 2) the distension of uterus was made dose dependently and significantly different in 1,000 mg/kg group (p.0.05) from control in the gross findings, 3) the weight of uterus was increased in 1,000 mg/kg group, and 4) the action on reproductive tissues was clear in the microscopic findings in terms of hyperplasia of endometrial epithelial cell, cystic change of submucosa, dilatation of uterus (significantly increased in 1,000 kg/mg), and follicular cystic changes in ovary. As a result, FGF271 seemed to act as a phytoestrogen by inducing the change in ovary and uterus and by increasing the serum estrogen concentration.

폐경기 여성들에게 있어서 에스트로겐의 결핍현상은 골다공증, 동맥경화, 심장질환과 같은 치명적인 질병을 유발하고, 혈관 운동 불안정으로 인하여 일과성 열감과 같은 증상이 일어나며, 치매의 위험이 있다. 또한, 안면홍조, 우울증, 무력감 등의 증상을 경험하는데, 식물성 에스트로겐 대체요법으로서 위와 같은 폐경기 증후군을 치유 예방 관리가 가능함과 동시에 동물성 혹은 화학적 에스트로겐 요법에서 우려되는 유방암 및 자궁암 등의 부작용에 대한 우려를 씻어낼 수 있다. 본 연구에서는 이와 같이 안전하면서 각종 폐경기 증후군에 대처할 수 있는 식물성 에스트로겐 대체제 (Phytoesoogen)의 효과를 확인하였다. 가장 고전적인 효과인 생식기 조직의 재생효과를 확인하였고, 혈중 에스트로겐 농도의 증가도 관찰되었다. 따라서 본 실험을 통해 확인된 여성호르몬 대체효과를 가지는 식물 추출물 FGF271이 추가의 연구를 통해 여성들이 인생의 1/3에 해당되는 폐경기를 즐겁고 안정된 삶으로 보낼 수 있도록 되기를 바란다.

Keywords

References

  1. Lievertz, R. W. (1987), Pharmacology and pharmacokinetics of estrogen, Am. J. Obstet. Gynecol. 156, 1289-1293 https://doi.org/10.1016/0002-9378(87)90166-9
  2. Anderson, F. (1993), Kinetics and pharmacology of estrogens in pre-and postmenopausal women, Int. J. Fertil. 38(suppl 1), 53-64
  3. Odonnell, M. B. (1995), Pharmacokinetic and pharmacologic variation between different estrogen products, J. Clin. Pharmacol. 35(suppl), 18S-24S https://doi.org/10.1002/j.1552-4604.1995.tb04143.x
  4. Kuiper, G. G., B. Carlsson, K. Grandien, E. Enmark, J. Haggblad, S. Nilsson, and J. A, Gustafsson (1997), Comparison of the ligand binding specificity andtranscript tissue distribution of estrogen receptors alpha and beta, Endocrinol. 138, 863-870 https://doi.org/10.1210/en.138.3.863
  5. Maddox, R. W., D. S. Carson, and C. L. Barnes (1998), Estrogens and postmenopausal women, US Pharmacist, 23, 141-150
  6. Guyton, A, C. and J. E. Hall (1996), Textbook of Medical Physiology, 9th ed., Elsevier, New York
  7. Stumpf, P, G. (1990), Pharmacokinetics of estrogen, Obstet. Gynecol., 75(4 suppl.), 9S-14S; discusion 15S-17S
  8. Barrett, J. (1996), Phytoestrogens: friends or foes?, Environ. Health. Perspect. 104, 478-482 https://doi.org/10.2307/3432986
  9. Proszkowiec, M. and J. Rzasa (2001), Variation in the ovarian and plasma progesterone and estradiol levels of the domestic hen during a pause in laying, Folia. BioI. (Krakow), 49, 285-289